TASK ORDER A16 - "Evaluation of Therapeutics and Vaccines in an Mpox Mouse Model"
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- No set-aside
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health's Division of Microbiology and Infectious Diseases plans a new requirement for Task Order A16, "Evaluation of Therapeutics and Vaccines in an Mpox Mouse Model," with an estimated solicitation release on June 1, 2026 and an estimated award on July 1, 2026. The task order will support in vivo evaluations of preventative and therapeutic candidates against Monkeypox virus, including evaluations against different Monkeypox viral clades, to prioritize products for further development and provide evidence of activity for FDA or other regulatory submissions. The forecast is classified under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).
The estimated award value range is $1.5 million to $3 million, and the forecast uses no set-aside. Contracting Officer Callie Prassinos (callie.prassinos@nih.gov, (240) 669-5155) and Erin Zeituni (erin.zeituni@nih.gov) are the listed federal points of contact at the National Institutes of Health.
Forecast text
The Division of Microbiology and Infectious Diseases plays a major role in the National Institute of Allergy and Infectious Diseases' effort to develop medical countermeasures for human viral diseases. Towards this purpose, this Task Order will support in vivo evaluations of preventative and therapeutic candidates against Monkeypox virus, which has recently caused global outbreaks and continues to evolve into clades that are more transmissible in humans. This virus is known to cause adverse pregnancy outcomes in infected women, and the newly emerging clades have recently been detected in the US. There are no therapeutics approved by the FDA for the treatment of disease caused by Monkeypox virus. In vivo Monkeypox virus infection models are intended to provide an assessment of candidate potency. Robust, reproducible, and predictive animal models that allow for evaluations of candidates against different Monkeypox viral clades are an essential tool to product developers. The data obtained from these studies will be used to prioritize products for further development, and to provide evidence of activity in data packages submitted to the FDA or other regulatory bodies. National Institute of Allergy and Infectious Diseases' preclinical services support medical countermeasures developers so that physicians will have more antiviral drugs and vaccines to choose from to treat the debilitating and deadly Monkeypox virus. If this request is not approved then it will delay future access to promising new products for the treatment of this disease.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast